Tag: unresectable intrahepatic cholangiocarcinoma
DOORwaY90 study signals strong efficacy and safety for SIR-Spheres in unresectable...
This advertorial is sponsored by Sirtex Medical.
Interim data from the DOORwaY90 study, a prospective, multicentre, open-label, single-arm trial evaluating SIR-Spheres yttrium-90 (Y-90) resin microspheres...
DOORwaY90 clinical trial interim analysis demonstrates efficacy of Y-90 resin microspheres...
An interim analysis of the DOORwaY90 clinical trial has shown that yttrium-90 (Y-90) resin microspheres—SIR-Spheres (Sirtex)—using partition dosimetry, achieved high objective response rates and...
New analysis benchmarks survival rates in unresectable intrahepatic cholangiocarcinoma patients undergoing...
Updating on a previous meta-analysis, new data which pooled survival estimates of patients undergoing transarterial radioembolization (TARE) has shown the treatment to be a...
